Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LMY-920 |
Synonyms | |
Therapy Description |
LMY-920 comprises autologous CD4- and CD8-positive T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing the B-cell activating factor (BAFF) ligand, which potentially induce cytotoxicity against tumor cells expressing BAFF-R (TNFRSF13C), BCMA (TNFRSF17), or TACI (TNFRSF13B) (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LMY-920 | LMY920|LMY 920|Autologous BAFF-expressing CAR T Cells | LMY-920 comprises autologous CD4- and CD8-positive T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing the B-cell activating factor (BAFF) ligand, which potentially induce cytotoxicity against tumor cells expressing BAFF-R (TNFRSF13C), BCMA (TNFRSF17), or TACI (TNFRSF13B) (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05546723 | Phase I | LMY-920 | LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002) | Recruiting | USA | 0 |
NCT05312801 | Phase I | LMY-920 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | Recruiting | USA | 0 |